{"id":62843,"date":"2026-03-25T22:02:21","date_gmt":"2026-03-25T21:02:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/"},"modified":"2026-03-25T22:02:21","modified_gmt":"2026-03-25T21:02:21","slug":"poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/","title":{"rendered":"Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Additional Tranche D PDR<sup>1<\/sup> bond financing from IPF for \u20ac3.75 million as part of the continuation plan validated by the Court of Economic Activities of Lyon.<\/b><\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>The Tranche D PDR bonds already issued and to be issued are simple bonds.<\/b><\/li>\n<\/ul>\n<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260325001000\/en\/729490\/5\/POXEL_LOGO_Q.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260325001000\/en\/729490\/22\/POXEL_LOGO_Q.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260325001000\/en\/729490\/5\/POXEL_LOGO_Q.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260325001000\/en\/729490\/21\/POXEL_LOGO_Q.jpg\"><\/a><\/p>\n<p>\nPOXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the &#8220;<b>Company<\/b>&#8220;), announces that it has signed, on March 25, 2026, the new Tranche D PDR subscription agreement with IPF Partners (&#8220;<b>IPF<\/b>&#8220;), for \u20ac3.75 million as part of the continuation plan approved by the Lyon Commercial Court (<i>Tribunal des activit\u00e9s \u00e9conomiques de Lyon<\/i>) on January 22, 2026.<\/p>\n<p>\nPoxel has already issued \u20ac0.5 million of Tranche D PDR bonds on February 16, 2026, and plans to issue an additional \u20ac0.5 million on March 26, 2026.<\/p>\n<p>\n<b>Key terms of the Tranche D PDR<\/b><\/p>\n<p>\nAs a reminder, Tranche D PDR results from a contractual amendment to Tranche D of the IPF bond financing entered into in September 2024, as amended in September 2025 to finance the observation period, and is intended to secure the Company&#8217;s operations as part of the continuation plan approved by the Lyon Commercial Court (<i>Tribunal des activit\u00e9s \u00e9conomiques de Lyon<\/i>) on January 22, 2026<sup>2<\/sup>.<\/p>\n<p>\nIn particular, it provides for the following stipulations as validated by the Lyon Commercial Court:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<span class=\"bwuline\">Tranche D PDR cash interest rate<\/span>: 0%;<\/li>\n<li>\n<span class=\"bwuline\">Capitalized interest rate of Tranche D PDR<\/span>: 35%;<\/li>\n<li>\n<span class=\"bwuline\">Commitment fee applicable to Tranche D PDR<\/span>: 10%;<\/li>\n<li>\n<span class=\"bwuline\">Exit fee of 13.7% applicable to Tranche D PDR (identical to Tranche D PO<sup>3<\/sup>)<\/span>: calculated based on the total amount of bonds issued;<\/li>\n<li>\n<span class=\"bwuline\">Allocation rate of Twymeeg royalties to be applied to the repayment of the IPF bond financing<\/span>: 90%;<\/li>\n<li>\n<span class=\"bwuline\">Conditions precedent<\/span>: in addition to the conditions already set out in the Tranche D documentation, the issuances under the Tranche D PDR are subject to the achievement of Imeglimin sales targets. The Company will also have the option of requesting a drawdown under this financing facility, subject in particular to a net available cash position of less than \u20ac500,000;<\/li>\n<li>\n<span class=\"bwuline\">Early redemption<\/span>: 50% of the proceeds of any licensing transaction relating to the assets transferred to the 2024 Residual Intellectual Property Security Trust will be used<sup>4<\/sup>, if requested by IPF, to repay the bonds of IPF, up to an overall ceiling of \u20ac20 million;<\/li>\n<li>\n<span class=\"bwuline\">Availability period<\/span>: Tranche D PDR will be available until the fifth anniversary of the adoption of the plan;<\/li>\n<li>\n<span class=\"bwuline\">Securities<\/span>: Tranche D PDR is secured by the trusts securing the IPF bond financing and, for \u20ac3.75 million, by the privilege provided for under Article L. 626-10 of the French Commercial Code.<\/li>\n<\/ul>\n<p>\nIn addition, the Company has committed to submit resolutions to Poxel&#8217;s next general meeting to authorize the issuance of share subscription warrants.<\/p>\n<p>\n<b>Prospects and security of financing<\/b><\/p>\n<p>\nThe purpose of the Tranche D PDR is to secure the financing of the Company&#8217;s operations as well as the settlement of its liabilities over the duration of the plan, in addition to the other financing operations and cost reductions envisaged, in particular:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nthe provision by IRIS of financing (known as &#8220;SmartATM\u00ae&#8221;) of a maximum amount of \u20ac5 million over 5 years, the terms of which are described in the appendix to a press release dated February 3, 2026<sup>5<\/sup> ;<\/li>\n<li>\na capital increase with shareholders&#8217; preferential subscription rights, open to Poxel&#8217;s shareholders and guaranteed by IPF;<\/li>\n<li>\na capital increase reserved for IPF Partners by way of set-off of receivables held in connection with the bond issue, making it possible to significantly reduce the Company&#8217;s debt, within the limit, for IPF and following the completion of these two capital increases, of the threshold of 29.9% of the Company&#8217;s share capital; and<\/li>\n<li>\nthe issuance of share subscription warrants for the benefit of shareholders.<\/li>\n<\/ul>\n<p>\n<b>About Poxel SA<\/b><\/p>\n<p>\nPoxel is a <b>clinical stage biopharmaceutical Company<\/b> developing <b>innovative treatments<\/b> <b>for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH)<\/b> and rare disorders. For the treatment of MASH, <b>PXL065<\/b> (deuterium-stabilised Rpioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of <b>PXL770<\/b>, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). <b>TWYMEEG<sup>\u00ae<\/sup><\/b> (Imeglimin), Poxel\u2019s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and 5 sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.<\/p>\n<p>\nFor more information, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=54464598&amp;newsitemid=20260325001000&amp;lan=en-US&amp;anchor=www.poxelpharma.com&amp;index=1&amp;md5=afbd6373ae5d7f73eea6346a5dadd331\" rel=\"nofollow\" shape=\"rect\">www.poxelpharma.com<\/a><\/p>\n<p>\nAll statements other than statements of historical fact included in this press release concerning future events are subject to (i) change without notice and (ii) factors beyond the Company&#8217;s control. These statements may include, but are not limited to, any statements preceded by, followed by, or including words such as \u2018objective,\u2019 \u2018believe,\u2019 \u2018expect,\u2019 \u2018aim,\u2019 \u2018intend,\u2019 \u2018may,\u2019 \u2018anticipate,\u2019 \u2018estimate,\u2019 \u2018plan,\u2019 \u2018project,\u2019 \u2018will,\u2019 \u2018could,\u2019 \u2018likely,\u2019 \u2018should,\u2019 and other words and terms of similar meaning, or the negative form of these words and terms. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company&#8217;s control that could cause the Company&#8217;s actual results or performance to differ materially from the results or performance expected, expressed or implied in such forward-looking statements. Actual events or results may differ from those described in this document due to a number of risks or uncertainties described in the Company&#8217;s 2024 Universal Registration Document available on the Company&#8217;s website and that of the AMF (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.amf-france.org%2Ffr&amp;esheet=54464598&amp;newsitemid=20260325001000&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.amf-france.org%2Ffr&amp;index=2&amp;md5=4f2be437985b767c196abda39cc16cee\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.amf-france.org\/fr<\/a>). The Company does not endorse and is not responsible for the content of external hyperlinks mentioned in this press release.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n___________________________________<br \/>\n<br \/><i><sup>1<\/sup> Tranche D PDR was the subject of a communication dated 24 November 2025 (<\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a%2Fpoxelpharma%2Fdb%2F422%2F4131%2Fpdf%2FCP_Poxel%2B-%2Bplan%2Bde%2Bredressement%2B-%2Bfinancement%2B-%2Bwebinaire%2B-%2B24.11.2025%2B-%2Bfinal.pdf&amp;esheet=54464598&amp;newsitemid=20260325001000&amp;lan=en-US&amp;anchor=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a%2Fpoxelpharma%2Fdb%2F422%2F4131%2Fpdf%2FCP_Poxel%2B-%2Bplan%2Bde%2Bredressement%2B-%2Bfinancement%2B-%2Bwebinaire%2B-%2B24.11.2025%2B-%2Bfinal.pdf&amp;index=3&amp;md5=063afaa04bd40fe9c3d252863e754ad9\" rel=\"nofollow\" shape=\"rect\"><i>https:\/\/d1io3yog0oux5.cloudfront.net\/_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a\/poxelpharma\/db\/422\/4131\/pdf\/CP_Poxel+-+plan+de+redressement+-+financement+-+webinaire+-+24.11.2025+-+final.pdf<\/i><\/a><i>).<br \/>\n<br \/><\/i><i><sup>2<\/sup> The end of the receivership procedure was the subject of a communication dated January 30, 2026: <\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a%2Fpoxelpharma%2Fdb%2F422%2F4149%2Fpdf%2FCP%2B-%2BPOXEL_Validation%2Bdu%2Bplan%2Bde%2Bcontinuation.pdf&amp;esheet=54464598&amp;newsitemid=20260325001000&amp;lan=en-US&amp;anchor=CP%2B-%2BPOXEL_Validation%2Bdu%2Bplan%2Bde%2Bcontinuation.pdf&amp;index=4&amp;md5=6e1032cf4b21afbfeaab6a3104950a6f\" rel=\"nofollow\" shape=\"rect\"><i>CP+-+POXEL_Validation+du+plan+de+continuation.pdf<\/i><\/a><i> (<\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a%2Fpoxelpharma%2Fdb%2F422%2F4149%2Fpdf%2FCP%2B-%2BPOXEL_Validation%2Bdu%2Bplan%2Bde%2Bcontinuation.pdf&amp;esheet=54464598&amp;newsitemid=20260325001000&amp;lan=en-US&amp;anchor=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a%2Fpoxelpharma%2Fdb%2F422%2F4149%2Fpdf%2FCP%2B-%2BPOXEL_Validation%2Bdu%2Bplan%2Bde%2Bcontinuation.pdf&amp;index=5&amp;md5=2db2d4aa34ce077fa42e0dd0eacd73ff\" rel=\"nofollow\" shape=\"rect\"><i>https:\/\/d1io3yog0oux5.cloudfront.net\/_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a\/poxelpharma\/db\/422\/4149\/pdf\/CP+-+POXEL_Validation+du+plan+de+continuation.pdf<\/i><\/a><i>).<br \/>\n<br \/><\/i><i><sup>3<\/sup> The availability of the Tranche D PO bond was communicated on 29 September 2025 (<\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a%2Fpoxelpharma%2Fdb%2F422%2F4115%2Fpdf%2FPoxel_%2Bnouveau%2Bfinancement%2Bobligataire.pdf&amp;esheet=54464598&amp;newsitemid=20260325001000&amp;lan=en-US&amp;anchor=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a%2Fpoxelpharma%2Fdb%2F422%2F4115%2Fpdf%2FPoxel_%2Bnouveau%2Bfinancement%2Bobligataire.pdf&amp;index=6&amp;md5=611495fbc79812a1621ac2ef246af37d\" rel=\"nofollow\" shape=\"rect\"><i>https:\/\/d1io3yog0oux5.cloudfront.net\/_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a\/poxelpharma\/db\/422\/4115\/pdf\/Poxel_+nouveau+financement+obligataire.pdf<\/i><\/a><i>).<br \/>\n<br \/><\/i><i><sup>4<\/sup> Tranche D PDR was the subject of a communication dated 24 November 2025 (<\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a%2Fpoxelpharma%2Fdb%2F422%2F4131%2Fpdf%2FCP_Poxel%2B-%2Bplan%2Bde%2Bredressement%2B-%2Bfinancement%2B-%2Bwebinaire%2B-%2B24.11.2025%2B-%2Bfinal.pdf&amp;esheet=54464598&amp;newsitemid=20260325001000&amp;lan=en-US&amp;anchor=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a%2Fpoxelpharma%2Fdb%2F422%2F4131%2Fpdf%2FCP_Poxel%2B-%2Bplan%2Bde%2Bredressement%2B-%2Bfinancement%2B-%2Bwebinaire%2B-%2B24.11.2025%2B-%2Bfinal.pdf&amp;index=7&amp;md5=d9ca168ae3a3003daa4f032c5ef1d49a\" rel=\"nofollow\" shape=\"rect\"><i>https:\/\/d1io3yog0oux5.cloudfront.net\/_eaa0a2c7c9bbce8ea5e37b93ea4f7c5a\/poxelpharma\/db\/422\/4131\/pdf\/CP_Poxel+-+plan+de+redressement+-+financement+-+webinaire+-+24.11.2025+-+final.pdf<\/i><\/a><i>).<br \/>\n<br \/><\/i><i><sup>5<\/sup> The establishment of an equity financing line with IRIS as part of the implementation of the continuation plan was communicated on 3 February 2026 (<\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_a49d11eb0dd5f3c820cab7e785c6259c%2Fpoxelpharma%2Fdb%2F422%2F4151%2Fpdf%2FPoxel%2B-%2BCP%2B-%2BEmission%2BEquity%2BLine%2B03022026.pdf&amp;esheet=54464598&amp;newsitemid=20260325001000&amp;lan=en-US&amp;anchor=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_a49d11eb0dd5f3c820cab7e785c6259c%2Fpoxelpharma%2Fdb%2F422%2F4151%2Fpdf%2FPoxel%2B-%2BCP%2B-%2BEmission%2BEquity%2BLine%2B03022026.pdf&amp;index=8&amp;md5=0b8014dcadc451352c333e64b11c5762\" rel=\"nofollow\" shape=\"rect\"><i>https:\/\/d1io3yog0oux5.cloudfront.net\/_a49d11eb0dd5f3c820cab7e785c6259c\/poxelpharma\/db\/422\/4151\/pdf\/Poxel+-+CP+-+Emission+Equity+Line+03022026.pdf<\/i><\/a><i>).<\/i><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n\u00a0<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Contacts &#8211; Investor relations \/ Media<\/b><\/p>\n<p>\nNewCap<br \/>\n<br \/>Th\u00e9o Martin \/ Paul Boivin<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;t&#x6f;&#x3a;&#x69;&#110;&#118;e&#x73;&#x74;&#x6f;&#114;&#115;&#64;&#x70;&#x6f;&#x78;&#101;&#108;p&#x68;&#x61;&#x72;&#109;a&#46;&#x63;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x69;&#x6e;&#x76;&#101;&#115;to&#x72;&#x73;&#x40;&#x70;&#111;&#120;el&#x70;&#x68;&#x61;&#114;&#109;&#97;&#46;c&#x6f;&#x6d;<\/a><br \/>+33 1 44 71 94 94<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Additional Tranche D PDR1 bond financing from IPF for \u20ac3.75 million as part of the continuation plan validated by the Court of Economic Activities of Lyon. The Tranche D PDR bonds already issued and to be issued are simple bonds. LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical-stage biopharmaceutical company that &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62843","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Additional Tranche D PDR1 bond financing from IPF for \u20ac3.75 million as part of the continuation plan validated by the Court of Economic Activities of Lyon. The Tranche D PDR bonds already issued and to be issued are simple bonds. LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical-stage biopharmaceutical company that ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-25T21:02:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260325001000\/en\/729490\/22\/POXEL_LOGO_Q.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan\",\"datePublished\":\"2026-03-25T21:02:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/\"},\"wordCount\":1221,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260325001000\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/\",\"name\":\"Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260325001000\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\",\"datePublished\":\"2026-03-25T21:02:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260325001000\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260325001000\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/","og_locale":"en_US","og_type":"article","og_title":"Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan - Pharma Trend","og_description":"Additional Tranche D PDR1 bond financing from IPF for \u20ac3.75 million as part of the continuation plan validated by the Court of Economic Activities of Lyon. The Tranche D PDR bonds already issued and to be issued are simple bonds. LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical-stage biopharmaceutical company that ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-25T21:02:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260325001000\/en\/729490\/22\/POXEL_LOGO_Q.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan","datePublished":"2026-03-25T21:02:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/"},"wordCount":1221,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260325001000\/en\/729490\/22\/POXEL_LOGO_Q.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/","url":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/","name":"Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260325001000\/en\/729490\/22\/POXEL_LOGO_Q.jpg","datePublished":"2026-03-25T21:02:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260325001000\/en\/729490\/22\/POXEL_LOGO_Q.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260325001000\/en\/729490\/22\/POXEL_LOGO_Q.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62843"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62843\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}